Sign inJoin waitlistJoin the waitlist

Brian Rini

Professor of Medicine · Vanderbilt University Medical Center

Credentials: · · · ·

History

Vanderbilt University Medical Center
Present

Hematology and Medical Oncology
University of Chicago Medical Center
1998–2001
Internal Medicine
University of Chicago Medical Center
1995–1998
Ohio State Univ Coll of Med
1991–1995

Research

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
New England Journal of Medicine · 2018 · 3,758 citations
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
New England Journal of Medicine · 2019 · First of 28 authors · 2,745 citations
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
New England Journal of Medicine · 2019 · 1,993 citations

Toni Choueiri
106 papers · 4 as a fellow
RM
Robert Motzer
75 papers
Jorge Garcia
70 papers · 14 as a resident
David McDermott
59 papers
Michael Atkins
54 papers
DH
Daniel Heng
49 papers
Sumanta Pal
46 papers
Moshe Ornstein
41 papers · 21 as a fellow
RB
Ronald Bukowski
39 papers
Eric Small
38 papers
Elizabeth Plimack
33 papers
Robert Dreicer
31 papers

Grants

Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $504.3K · Vanderbilt University Medical Center
1998–2027
Therapeutic Modulation of COX-2-Induced Immunosuppression in Metastatic RCC
National Cancer Institute · R21
Contact PI · $587.1K · Cleveland Clinic Lerner Com-Cwru
2007–2010
Case Comprehensive Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $109.5K · Case Western Reserve University

Clinical trials

Pilot Study of Casdatifan-Treated Refractory Renal Cell Carcinoma
Principal investigator · Not yet recruiting · Early phase 1
Vanderbilt-Ingram Cancer Center
2029–2031
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Principal investigator · Recruiting · Phase 2
Brian Rini
2026–2030
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Principal investigator · Recruiting · Phase 2
Vanderbilt-Ingram Cancer Center
2022–2028
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Principal investigator · Recruiting
Adela, Inc
2022–2027